Source comparison
Peptides for Stroke Recovery: Mechanism Comparison
Cerebrolysin BDNF/NGF mimetic. Activates TrkB receptors, reduces excitotoxicity and apoptosis 0–72 hours post-stroke (acute neuroprotection) Strong. Multiple Phase III RCTs with NIHSS improvement data Acute ischemic stroke with large penumbra volume; administe
This comparison does not assign a generated winner or score.
- Cerebrolysin
- BDNF/NGF mimetic. Activates TrkB receptors, reduces excitotoxicity and apoptosis
- 0–72 hours post-stroke (acute neuroprotection)
- Strong. Multiple Phase III RCTs with NIHSS improvement data
- Acute ischemic stroke with large penumbra volume; administered IV during hospitalization
- Dihexa
- HGF/c-Met pathway potentiation. Enhances synaptogenesis and dendritic spine density
- 1–12 weeks post-stroke (subacute neuroplasticity)
- Moderate. Animal models robust, human trials limited to case series
- Motor recovery and cognitive rehabilitation during outpatient therapy phase
- P21
- CNTF-derived neurogenesis promoter. Increases neural progenitor migration to injury site
- 2–8 weeks post-stroke (subacute to chronic recovery)
- Limited. Preclinical only, human data observational
- Cognitive deficits and executive function impairment; research peptide status
- Thymalin
- Thymic peptide. Immune modulation and systemic inflammation reduction
- Chronic phase (>3 months post-stroke)
- Emerging. Eastern European trials show secondary prevention benefit
- Reducing systemic inflammation in chronic stroke survivors with ongoing immune dysregulation